MedTrace Logo

Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS

NCT07498634 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 323

Last updated 2026-03-27

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, and parallel grouping study.

Study procedures: The screening period does not exceed 4 weeks, including 16 weeks for initial treatment, 28 weeks for maintenance treatment and 8 weeks for safety follow-up.

Conditions

  • Phase III

Interventions

DRUG

XKH004

Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Zhejiang Kanova Biopharmaceutical Co., LTD

    lead INDUSTRY

Principal Investigators

  • Huji Xu, PHD · Shanghai Changzheng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2025-08-01
Completion
2025-11-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07498634 on ClinicalTrials.gov